We are live on
!
Find out more
ACM
Altium Capital Management Portfolio holdings
AUM
$42M
This Fund
S&P 500
This Quarter
Est. Return
+27.43%
1 Year Est. Return
–
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$197M
AUM Growth
-$76M
(-28%)
Cap. Flow
-$97.6M
Cap. Flow
% of AUM
-49.58%
Top 10 Holdings %
Top 10 Hldgs %
44.5%
Holding
160
New
26
Increased
14
Reduced
15
Closed
66
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
ATXS
Astria Therapeutics
ATXS
|
+$9.39M |
| 2 |
Tandem Diabetes Care
TNDM
|
+$4.07M |
| 3 |
Amylyx Pharmaceuticals
AMLX
|
+$3.73M |
| 4 |
Outlook Therapeutics
OTLK
|
+$3.62M |
| 5 |
Replimune Group
REPL
|
+$3.32M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
CCXI
ChemoCentryx, Inc.
CCXI
|
+$8.27M |
| 2 |
Insmed
INSM
|
+$5.77M |
| 3 |
MBTC
Nocturne Acquisition Corporation Ordinary Shares
MBTC
|
+$5.17M |
| 4 |
BioAtla
BCAB
|
+$4.26M |
| 5 |
Illumina
ILMN
|
+$4.2M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 88.67% |
| 2 | Financials | 5.8% |
| 3 | Communication Services | 0.42% |
| 4 | Industrials | 0.36% |
| 5 | Materials | 0.29% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
JBIO
101
Jade Biosciences
JBIO
$1.34B
| – | – |
-1,457
| Closed | -$846K |
|
|
102
BioAtla
BCAB
$5.74M
| – | – |
-11,060
| Closed | -$4.26M |
|
103
Benitec Biopharma
BNTC
$468M
| – | – |
-38,753
| Closed | -$245K |
|
104
PUT
Clene
CLNN
$67.5M
| – | – |
-14,075
| Closed | -$788K |
|
105
Castle Biosciences
CSTL
$979M
| – | – |
-60,000
| Closed | -$1.56M |
|
106
EyePoint Inc
EYPT
$1.2B
| – | – |
-224,541
| Closed | -$1.78M |
|
107
CALL
Guardant Health
GH
$22.6B
| – | – |
-100,000
| Closed | -$5.38M |
|
|
108
Guardant Health
GH
$22.6B
| – | – |
-66,000
| Closed | -$3.55M |
|
109
Gossamer Bio
GOSS
$87M
| – | – |
-135,000
| Closed | -$1.62M |
|
110
Hillman Solutions
HLMN
$1.79B
| – | – |
-221,000
| Closed | -$1.67M |
|
|
111
Illumina
ILMN
$28.4B
| – | – |
-22,616
| Closed | -$4.2M |
|
112
Inogen
INGN
$164M
| – | – |
-146,000
| Closed | -$3.54M |
|
|
113
Insmed
INSM
$28.6B
| – | – |
-268,000
| Closed | -$5.77M |
|
114
Inspire Medical Systems
INSP
$1.74B
| – | – |
-12,000
| Closed | -$2.13M |
|
115
Karyopharm Therapeutics
KPTI
$48M
| – | – |
-50,000
| Closed | -$4.09M |
|
116
Keros Therapeutics
KROS
$221M
| – | – |
-88,000
| Closed | -$3.31M |
|
117
Lantheus
LNTH
$6.59B
| – | – |
-42,000
| Closed | -$2.95M |
|
118
Larimar Therapeutics
LRMR
$432M
| – | – |
-320,000
| Closed | -$1.02M |
|
|
SDEV
119
Stablecoin Development Corp
SDEV
$52M
| – | – |
-179
| Closed | -$121K |
|
120
Natera
NTRA
$46.4B
| – | – |
-75,000
| Closed | -$3.29M |
|
121
Ocular Therapeutix
OCUL
$2.02B
| – | – |
-517,133
| Closed | -$2.15M |
|
122
Palisade Bio
PALI
$367M
| – | – |
-7,524
| Closed | -$559K |
|
123
Procept Biorobotics
PRCT
$1.17B
| – | – |
-81,000
| Closed | -$3.36M |
|
124
QuidelOrtho
QDEL
$838M
| – | – |
-50,000
| Closed | -$3.57M |
|
125
uniQure
QURE
$3.22B
| – | – |
-105,000
| Closed | -$1.97M |
|
Similar funds
TA
SIM
VEPM
BCM
VAM
SCM
CAS
ICP
Altium Capital Management's Q4 2022 Portfolio in Review
As of Q4 2022, Altium Capital Management held 160 positions worth $197M, down 28% from $273M the previous quarter. Its ten largest holdings account for 45% of the portfolio.
Altium Capital Management withdrew a net $97.6M in Q4 2022, closing 66 positions and reducing 15 holdings. Its most notable exit was ChemoCentryx, Inc., an estimated $8.27M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 89% of assets, up from 79% a quarter earlier, followed by Financials and Communication Services.
Against the trend, Altium Capital Management opened a new position in Tandem Diabetes Care worth $4.05M.
- Altium Capital Management's largest Q4 2022 buy was Tandem Diabetes Care: 90,000 shares worth $4.05M.
- Altium Capital Management added most to Astria Therapeutics in Q4 2022, an estimated $9.39M increase.
- Altium Capital Management's biggest Q4 2022 reduction was Chinook Therapeutics, Inc. Common Stock, cutting an estimated $3.1M.
- Altium Capital Management fully exited ChemoCentryx, Inc. in Q4 2022, selling an estimated $8.27M.
- Altium Capital Management's ten largest holdings make up 45% of its $197M portfolio in Q4 2022.
- Altium Capital Management opened 26 new positions and closed 66 in Q4 2022.
- Altium Capital Management's portfolio value fell 28% quarter-over-quarter to $197M.
Based on Altium Capital Management's 13F filing for Q4 2022, filed 14 Feb 2023.